


## CLAIMS

## 1. Use of a compound of formula (I)



or a pharmaceutically acceptable salt or solvate thereof, in which:

**R<sup>1</sup>** is selected from the group consisting of H, C<sub>1-6</sub>alkyl, C<sub>1-2</sub>alkyl substituted by one to five fluorine atoms, C<sub>3-6</sub>alkenyl, C<sub>3-6</sub>alkynyl, C<sub>3-10</sub>cycloalkylC<sub>0-6</sub>alkyl, C<sub>4-12</sub>bridged cycloalkyl, A(CR<sup>4</sup>R<sup>5</sup>)<sub>n</sub> and B(CR<sup>4</sup>R<sup>5</sup>)<sub>n</sub>;

**R<sup>2</sup>** is C<sub>1-2</sub>alkyl substituted by one to five fluorine atoms;


**R<sup>3</sup>** is selected from the group consisting of C<sub>1-6</sub>alkyl, NH<sub>2</sub> and R<sup>7</sup>CONH;

**R<sup>4</sup> and R<sup>5</sup>** are independently selected from H or C<sub>1-6</sub>alkyl;

**A** is selected from the group consisting of unsubstituted 5- or 6-membered heteroaryl, unsubstituted 6-membered aryl, 5- or 6-membered heteroaryl substituted by one or more R<sup>6</sup> and 6-membered aryl substituted by one or more R<sup>6</sup>;

**R<sup>6</sup>** is selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl substituted by one more fluorine atoms, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkoxy substituted by one or more F, NH<sub>2</sub>SO<sub>2</sub> and C<sub>1-6</sub>alkylSO<sub>2</sub>;

**B** is a ring selected from the group consisting of




where  defines the point of attachment of the ring;

**R<sup>7</sup>** is selected from the group consisting of H, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylOC<sub>1-6</sub>alkyl, phenyl, HO<sub>2</sub>CC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylOCOC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylOCO, H<sub>2</sub>NC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylOCONHC<sub>1-6</sub>alkyl and C<sub>1-6</sub>alkylCONHC<sub>1-6</sub>alkyl; and

**n** is 0 to 4;

in the preparation of a medicament for the treatment of depressive disorders.


## 2. Use of a compound of formula (II)



or a pharmaceutically acceptable salt or solvate thereof in which:

- $Z^0$  is selected from the group consisting of halogen,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkoxy substituted by one or more fluorine atoms, and  $O(CH_2)_nNZ^4Z^5$ ;
- $Z^1$  and  $Z^2$  are each the same or different and are independently selected from the group consisting of H,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkyl substituted by one or more fluorine atoms,  $C_{1-6}$ alkoxy,  $C_{1-6}$ hydroxyalkyl,  $SC_{1-6}$ alkyl,  $C(O)H$ ,  $C(O)C_{1-6}$ alkyl,  $C_{1-6}$ alkylsulphonyl,  $C_{1-6}$ alkoxy substituted by one or more fluorine atoms,  $O(CH_2)_nCO_2C_{1-6}$ alkyl,  $O(CH_2)_nSC_{1-6}$ alkyl,  $(CH_2)_nNZ^4Z^5$ ,  $(CH_2)_nSC_{1-6}$ alkyl and  $C(O)NZ^4Z^5$ ; with the proviso that when  $Z^0$  is at the 4-position and is halogen, then at least one of  $Z^1$  and  $Z^2$  is  $C_{1-6}$ alkylsulphonyl,  $C_{1-6}$ alkoxy substituted by one or more fluorine atoms,  $O(CH_2)_nCO_2C_{1-6}$ alkyl,  $O(CH_2)_nSC_{1-6}$ alkyl,  $(CH_2)_nNZ^4Z^5$ ,  $(CH_2)_nSC_{1-6}$ alkyl or  $C(O)NZ^4Z^5$ ;
- $Z^3$  is  $C_{1-6}$ alkyl or  $NH_2$ ;
- $Z^4$  and  $Z^5$  are each the same or different and are independently selected from the group consisting of H, or  $C_{1-6}$ alkyl or,  $Z^4$  and  $Z^5$  together with the nitrogen atom to which they are bound, form a 4 - 8 membered saturated heterocyclic ring having 1 or 2 heteroatoms selected from N, O and S; and
- $n^1$  is 1-4;
- in the preparation of a medicament for the treatment of depressive disorders.


### 3. Use of a compound of formula (III)



or a pharmaceutically acceptable salt thereof in which:

- X is selected from the group consisting of oxygen or  $NQ^2$ ;

- Y is selected from the group consisting of CH or nitrogen;
- Q<sup>1</sup> is selected from the group consisting of H, C<sub>1-6</sub>alkyl, C<sub>1-2</sub>alkyl substituted by one to five fluorine atoms, C<sub>1-3</sub>alkylOC<sub>1-3</sub>alkyl, C<sub>3-6</sub>alkenyl, C<sub>3-6</sub>alkynyl, C<sub>3-10</sub>cycloalkylC<sub>0-6</sub>alkyl, C<sub>4-7</sub>cycloalkyl substituted by C<sub>1-3</sub>alkyl or C<sub>1-3</sub>alkoxy, C<sub>4-12</sub>bridged cycloalkyl, A(CR<sup>6</sup>R<sup>7</sup>)<sub>n</sub> and B(CR<sup>6</sup>R<sup>7</sup>)<sub>n</sub>;
- Q<sup>2</sup> is selected from the group consisting of H and C<sub>1-6</sub>alkyl; or
- Q<sup>1</sup> and Q<sup>2</sup> together with the nitrogen atom to which they are bound form a 4-8 membered saturated heterocyclic ring or a 5-membered heteroaryl ring heteroaryl ring is unsubstituted or substituted by one R<sup>8</sup>;
- Q<sup>3</sup> is selected from the group consisting of C<sub>1-5</sub>alkyl and C<sub>1-2</sub>alkyl substituted by one to five fluorine atoms;
- Q<sup>4</sup> is selected from the group consisting of C<sub>1-6</sub>alkyl, NH<sub>2</sub> and R<sup>9</sup>CONH;
- Q<sup>5</sup> is selected from the group consisting of hydrogen, C<sub>1-3</sub>alkyl, C<sub>1-2</sub>alkyl substituted by one to five fluorine atoms, C<sub>1-3</sub>alkylO<sub>2</sub>C, halogen, cyano, (C<sub>1-3</sub>alkyl)<sub>2</sub>NCO, C<sub>1-3</sub>alkylS and C<sub>1-3</sub>alkylO<sub>2</sub>S;
- Q<sup>6</sup> and Q<sup>7</sup> are independently H or C<sub>1-6</sub>alkyl;
- A<sup>1</sup> is selected from the group consisting of unsubstituted 5- or 6-membered heteroaryl unsubstituted 6-membered aryl, 5- or 6-membered heteroaryl substituted by one or more R<sup>8</sup>; and 6-membered aryl substituted by one or more R<sup>8</sup>;
- Q<sup>8</sup> is selected from the group consisting of halogen, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkyl substituted by one more fluorine atoms, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkoxy substituted by one or more F, NH<sub>2</sub>SO<sub>2</sub> and C<sub>1-6</sub>alkylSO<sub>2</sub>;
- B<sup>1</sup> is a ring selected from the group consisting of



and where  defines the point of attachment of the ring;

- Q<sup>9</sup> is selected from the group consisting of H, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylOC<sub>1-6</sub>alkyl, phenyl, HO<sub>2</sub>CC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylOCOC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylOCO, H<sub>2</sub>NC<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkylOCONHC<sub>1-6</sub>alkyl and C<sub>1-6</sub>alkylCONHC<sub>1-6</sub>alkyl;
- Q<sup>10</sup> is selected from the group consisting of H and halogen; and
- n is 0 to 4;

in the preparation of a medicament for the treatment of depressive disorders.

4. Use of a compound of formula (I), (II) and (III), as defined in anyone of claims from 1 to 3, or a pharmaceutically acceptable salts or solvates thereof, in combination with a selective serotonin inhibitor in the preparation of a medicament for the treatment of depressive disorders.

5. Use of a compound selected from the group consisting of:
- 2-(4-fluorophenoxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 2-(4-methoxyphenoxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 2-butoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 2-[(5-chloropyridin-3-yl)oxy]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 2-(cyclohexyloxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 3-(4-methylsulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 6-difluoromethoxy-2-(4-fluoro-phenyl)-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]-pyridazine;
  - 2-(4-ethoxy-phenyl)-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-fluoro-phenyl)-6-methylsulfonyl-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-difluoromethoxy-phenyl)-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 4-[2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazin-3-yl]-benzenesulfonamide;
  - 6-difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 3-(4-methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 6-difluoromethoxy-2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-fluoro-phenyl)-6-methanesulfonyl-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-difluoromethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 4-[2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazin-3-yl]-benzenesulfonamide;
  - 6-difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 4-ethyl-6-[4-(methylsulfonyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)-2-pyridinamine;
  - 4-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;
  - N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;
  - N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;
  - 4-(6-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]amino)-4-ethyl-2-pyridinyl)benzenesulfonamide;
  - N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;
  - N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;
  - 4-[4-methyl-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-2-pyridinyl]-benzenesulfonamide;
  - 4-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;

N-(cyclohexylmethyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-cyclohexyl-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 2-[4-(methylsulfonyl)phenyl]-6-[(2-pyridinylmethyl)oxy]-4-(trifluoromethyl)pyridine;  
 4-methyl-N-[(3-methyl-4-isoxazolyl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 6-[4-(methylsulfonyl)phenyl]-N-(2-pyridinylmethyl)-4-(trifluoromethyl)-2-pyridinamine;  
 N-cycloheptyl-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-(cis-4-methylcyclohexyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-(1-ethylpropyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 4-methyl-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 N-(cyclopentylmethyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-[(1-ethyl-1H-1,2,4-triazol-5-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[(2-pyridinylmethyl)amino]-3-pyridinecarbonitrile;  
 4-ethyl-2-[(5-methyl-2-pyridinyl)methyl]amino-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;  
 4-ethyl-2-[(6-methyl-3-pyridinyl)methyl]amino-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;  
 4-ethyl-2-[(1-methyl-1H-pyrazol-4-yl)methyl]amino-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;  
 4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[(4-methyl-1,3-thiazol-2-yl)methyl]amino-3-pyridinecarbonitrile;  
 4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[(2-pyridinylmethyl)oxy]-3-pyridinecarbonitrile;  
 4-ethyl-N-[(1-ethyl-1H-1,2,4-triazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 4-ethyl-2-[(6-methyl-3-pyridinyl)methyl]oxy-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;  
 6-[4-(methylsulfonyl)phenyl]-N-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-4-(trifluoromethyl)-2-pyridinamine; and pharmaceutically acceptable salts and solvates thereof in the preparation of a medicament for the treatment of depressive disorders.

6. Use according to Claim 5, wherein the compound is 2-butoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine or a pharmaceutical acceptable salt or solvate thereof.
7. Use according to Claim 4, characterised in that the selective serotonin inhibitor is selected from citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, duloxetine, dapoxetine, nefazodone, imipramine, imipramine

N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, WY 27587, WY 27866, imeldine, ifoxetine, tiflucarbine, viqualine, milnacipran, bazinaprine, YM 922, S 33005, F 98214-TA, OPC 14523, alaproclate, cyanodothepine, trimipramine, quinupramine, dothiepin, amoxapine, nitroxazepine, McN 5652, McN 5707, VN 2222, L 792339, roxindole, YM 35992,0177, Org 6582, Org 6997, Org 6906, amitriptyline, amitriptyline N-oxide, nortriptyline, CL 255.663, pirlindole, indatraline, LY 113.821, LY 214.281, CGP 6085 A, RU 25.591, napamezole, diclofensine, trazodone, EMD 68.843, BMY 42.569, NS 2389, sercloremin, nitroquipazine, ademethionine, sibutramine, clovoxamine, and mixtures thereof.

8. Use according to Claim 4, wherein the selective serotonin inhibitor is paroxetine.
9. Use of 2-butoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine or a pharmaceutical acceptable salt thereof, in combination with paroxetine in the preparation of a medicament for the treatment of depressive disorders.
10. A method for the treatment of a depressive disorder in a mammal in need thereof, said method comprising administering to said patient an effective amount of a first component which is of a compound according to any of claims 1-3, in combination with an effective amount of a second component which is a selective serotonin reuptake inhibitor.
11. The method according to claim 10, wherein said mammal is human.
12. The method according to claim 11, wherein said depressive disorder is selected from the group: bipolar disorder, bipolar depression, bipolar disorder I, bipolar disorder II, unipolar depression.
13. The method according to claim 10, wherein said selective serotonin inhibitor is selected from citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, duloxetine, dapoxetine, nefazodone, imipramine, imipramine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, WY 27587, WY 27866, imeldine, ifoxetine, tiflucarbine, viqualine, milnacipran, bazinaprine, YM 922, S 33005, F 98214-TA, OPC 14523, alaproclate, cyanodothepine, trimipramine, quinupramine, dothiepin, amoxapine, nitroxazepine, McN 5652, McN 5707, VN 2222, L 792339, roxindole, YM 35992,0177, Org 6582, Org 6997, Org 6906, amitriptyline, amitriptyline N-oxide, nortriptyline, CL 255.663, pirlindole, indatraline, LY 113.821, LY 214.281, CGP 6085 A, RU 25.591, napamezole, diclofensine, trazodone, EMD 68.843, BMY 42.569, NS 2389, sercloremin, nitroquipazine, ademethionine, sibutramine, clovoxamine, and mixtures thereof.

14. The method according to claim 10, wherein said selective serotonin inhibitor is paroxetine.
15. The method according to claim 10, wherein said first component is a compound selected from the group consisting of:
  - 2-(4-fluorophenoxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 2-(4-methoxyphenoxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 2-butoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 2-[(5-chloropyridin-3-yl)oxy]-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 2-(cyclohexyloxy)-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine;
  - 3-(4-methylsulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 6-difluoromethoxy-2-(4-fluoro-phenyl)-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]-pyridazine;
  - 2-(4-ethoxy-phenyl)-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-fluoro-phenyl)-6-methylsulfonyl-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-difluoromethoxy-phenyl)-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 4-[2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazin-3-yl]-benzenesulfonamide;
  - 6-difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methylsulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 3-(4-methanesulfonyl-phenyl)-2-(4-methoxy-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 6-difluoromethoxy-2-(4-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-fluoro-phenyl)-6-methanesulfonyl-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 2-(4-difluoromethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 4-[2-(4-ethoxy-phenyl)-pyrazolo[1,5-b]pyridazin-3-yl]-benzenesulfonamide;
  - 6-difluoromethoxy-2-(3-fluoro-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine;
  - 4-ethyl-6-[4-(methylsulfonyl)phenyl]-N-(tetrahydro-2H-pyran-4-ylmethyl)-2-pyridinamine;
  - 4-methyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;
  - N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;
  - N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;
  - 4-(6-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]amino)-4-ethyl-2-pyridinyl)benzenesulfonamide;
  - N-[(1,3-dimethyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;
  - N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;

4-[4-methyl-6-[(tetrahydro-2H-pyran-4-yl)methyl]amino]-2-pyridinyl]benzenesulfonamide;  
 4-methyl-N-[(1-methyl-1H-pyrazol-3-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 N-(cyclohexylmethyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-cyclohexyl-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 2-[4-(methylsulfonyl)phenyl]-6-[(2-pyridinylmethyl)oxy]-4-(trifluoromethyl)pyridine;  
 4-methyl-N-[(3-methyl-4-isoxazolyl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 6-[4-(methylsulfonyl)phenyl]-N-(2-pyridinylmethyl)-4-(trifluoromethyl)-2-pyridinamine;  
 N-cycloheptyl-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-(cis-4-methylcyclohexyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-(1-ethylpropyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-[(3-methyl-1,2,4-oxadiazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 4-methyl-N-[(1-methyl-1H-pyrazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 N-(cyclopentylmethyl)-6-[4-(methylsulfonyl)phenyl]-4-(trifluoromethyl)-2-pyridinamine;  
 N-[(1-ethyl-1H-1,2,4-triazol-5-yl)methyl]-4-methyl-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[(2-pyridinylmethyl)amino]-3-pyridinecarbonitrile;  
 4-ethyl-2-[[[(5-methyl-2-pyridinyl)methyl]amino]-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;  
 4-ethyl-2-[[[(6-methyl-3-pyridinyl)methyl]amino]-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;  
 4-ethyl-2-[[[(1-methyl-1H-pyrazol-4-yl)methyl]amino]-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;  
 4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[[[(4-methyl-1,3-thiazol-2-yl)methyl]amino]-3-pyridinecarbonitrile;  
 4-ethyl-6-[4-(methylsulfonyl)phenyl]-2-[(2-pyridinylmethyl)oxy]-3-pyridinecarbonitrile;  
 4-ethyl-N-[(1-ethyl-1H-1,2,4-triazol-5-yl)methyl]-6-[4-(methylsulfonyl)phenyl]-2-pyridinamine;  
 4-ethyl-2-[[[(6-methyl-3-pyridinyl)methyl]oxy]-6-[4-(methylsulfonyl)phenyl]-3-pyridinecarbonitrile;  
 6-[4-(methylsulfonyl)phenyl]-N-[(1-methyl-1H-1,2,4-triazol-5-yl)methyl]-4-(trifluoromethyl)-2-pyridinamine; and pharmaceutically acceptable salts and solvates thereof.

16. The method according to claim 10, wherein the said first component is the compound 2-butoxy-4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)pyrimidine and the second component is paroxetine.